Fabrice Branle

Results of the ASCEND-7 phase II study evaluating ALK inhibitor (ALKi) ceritinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) metastatic to the brain

H. Wakelee, C. Chiu, L. Chow, 2019, Annals of Oncology.

Efficacy and safety of ceritinib in ALK-positive non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): Results from the phase II, ASCEND-7 study

P. Wen, H. Wakelee, L. Chow, 2019, Annals of Oncology.